Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

Journal: Nature Medicine

Published: 2020-10-05

DOI: 10.1038/s41591-020-1082-2

Affiliations: 24

Authors: 21

Go to article
Institutions Share
Novartis Institutes for Biomedical Research (NIBR), United States of America (USA) 0.10
Novartis Pharmaceuticals Corporation, United States of America (USA) 0.10
University Hospital Zurich (UHZ), Switzerland 0.05
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Italy 0.05
Novartis International AG, Switzerland 0.05
Azienda Ospedaliera Papa Giovanni XXIII, Italy 0.05
Mount Vernon Cancer Centre, United Kingdom (UK) 0.05
Hospital Clinic of Barcelona, Spain 0.05
Medical University of Graz (Med Uni Graz), Austria 0.05
National Cancer Center Hospital, Japan 0.05
Novartis Health Care Pvt. Ltd., India 0.05
Massachusetts General Hospital (MGH), United States of America (USA) 0.05
University of California, Los Angeles (UCLA), United States of America (USA) 0.05
The University of Texas MD Anderson Cancer Center, United States of America (USA) 0.05
The University of Sydney (USYD), Australia 0.02
German Consortium of Translational Cancer Research (DKTK), Germany 0.02
Essen University Hospital, Germany 0.02
Hôpital Saint-Louis, France 0.02
University of Paris-Sud (UPSud), France 0.02
Institute Gustave-Roussy (IGR), France 0.02
The University of Queensland (UQ), Australia 0.02
Greenslopes Private Hospital, Australia 0.02
University of Paris, France 0.02
St Vincent's Health Australia, Australia 0.02